AC Immune SA Stock News

The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts

Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.

AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.

Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.

Undeniably, the concept of growth penny stocks represent one of the hottest topics on Wall Street. And this interest goes well beyond the meme-stock phenomenon that characterized much of the market ac

Here is how AC Immune (ACIU) and Exact Sciences (EXAS) have performed compared to their sector so far this year.

AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering p

Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneer

AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

AC Immune (ACIU) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago.

AC Immune to Present at the B TIG Virtual Biotechnology Conference 2023